M. Espié

发表

Do clinical , histological or immunohistochemical primary tumor characteristics translate into different 18 FDG-PET / CT volumetric and heterogeneity features in stage II-III breast cancer ?

M. Hatt, F. Tixier, D. Visvikis, 2015 .

Comparison Between 18F-FDG PET Image–Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer

M. Hatt, D. Visvikis, D. Groheux, 2013, The Journal of Nuclear Medicine.

Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer

D. Groheux, M. Espié, A. Roquancourt, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

The Yield of 18F-FDG PET/CT in Patients with Clinical Stage IIA, IIB, or IIIA Breast Cancer: A Prospective Study

D. Groheux, M. Espié, E. Hindié, 2011, The Journal of Nuclear Medicine.

Performance of FDG PET/CT in the clinical management of breast cancer.

D. Groheux, M. Espié, E. Hindié, 2013, Radiology.

18F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging

D. Groheux, P. Merlet, M. Espié, 2013, The Journal of Nuclear Medicine.

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

D. Groheux, A. Martineau, P. Merlet, 2017, Breast Cancer Research.

Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients

D. Groheux, A. Martineau, P. Merlet, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

p53 mutations and overexpression in locally advanced breast cancers.

M. Espié, M. Marty, P. de Cremoux, 1994, British Journal of Cancer.

A Review of the Antitumour Activity of Vinorelbine in Breast Cancer

M. Espié, M. Marty, V. Diéras, 2012, Drugs.

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

M. Espié, J. Baselga, P. Hoff, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation between MRI and biopsies under second look ultrasound.

M. Espié, C. de Bazelaire, S. Giachetti, 2014, Diagnostic and interventional imaging.

Comparison Between 18 F-FDG PET Image-Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer

M. Hatt, D. Visvikis, C. Rest, 2017 .

Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study

M. Espié, C. Cuénod, N. Siauve, 2011, BMC Cancer.

Combining molecular targeted therapies: clinical experience

M. Espié, M. Marty, X. Pivot, 2011, Anti-cancer drugs.

The management of breast cancer.

M. Espié, 2014, Diagnostic and interventional imaging.

Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy

M. Espié, M. Marty, F. Joly, 2000, British Journal of Cancer.

Ductal carcinoma in situ (DCIS) treated by mastectomy, or local excision with or without radiotherapy: A monocentric, retrospective study of 608 women.

M. Espié, R. Porcher, A. de Roquancourt, 2016, Breast.

¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.

D. Groheux, P. Merlet, M. Espié, 2014, European journal of radiology.

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

M. Espié, M. Mathieu, F. Reyal, 2017, European journal of cancer.

Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2− Breast Cancer

M. Hatt, D. Visvikis, M. Majdoub, 2015, The Journal of Nuclear Medicine.

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches

M. Espié, A. Roquancourt, A. de Roquancourt, 2011, British Journal of Cancer.

Phase I study of oxaliplatin in patients with advanced cancer

M. Espié, C. Fermé, M. Marty, 2004, Cancer Chemotherapy and Pharmacology.

Prospects with docetaxel in the treatment of patients with breast cancer.

M. Espié, M. Marty, J. Extra, 1997, European journal of cancer.

Breast cancer in patients under 18 years. Report of an inflammatory case and review of the literature

M. Espié, M. Marty, C. Louvet, 1996 .

Hormonal Treatment of Breast Cancer

M. Espié, S. Bécourt, 2019, Encyclopedia of Endocrine Diseases.

First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.

M. Espié, N. Bogdanova, V. Semiglazov, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment

M. Hatt, D. Groheux, M. Espié, 2013, British Journal of Cancer.

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.

M. Espié, C. Sotiriou, C. Desmedt, 2010, The oncologist.

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

J. S. Kim, M. Espié, Sung-Bae Kim, 2021, Breast Cancer Research and Treatment.

Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy

M. Espié, A. Roquancourt, M. Marty, 2002, The Lancet.

[Mass screening for breast cancer].

M. Espié, P. Cottu, C. Cuvier, 2003, Presse medicale.

[Epidemiology and risk factors of breast cancer].

M. Espié, F. Coussy, M. Lalloum, 2013, Soins; la revue de reference infirmiere.

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.

M. Espié, F. Bidard, J. Pierga, 2020, JAMA oncology.

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

M. Espié, M. Bollet, F. Bidard, 2019, Breast Cancer Research.

Abstract P2-02-17: T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial

M. Espié, M. Bollet, G. Romieu, 2016 .

Should FDG PET/CT be used for the initial staging of breast cancer?

D. Groheux, M. Espié, E. Hindié, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer

M. Espié, M. Namer, P. Fumoleau, 2001, Oncology.

Pregnancy, fertility concerns, and fertility preservation procedures in French breast cancer survivors in the FEERIC national study (on behalf of the Seintinelles research network).

M. Espié, F. Reyal, B. Asselain, 2021, medRxiv.

Intraoperative Radiotherapy for Breast Cancer in Elderly Women.

M. Espié, L. Quéro, S. Giacchetti, 2021, Clinical breast cancer.

10-Year follow-up of 621 patients treated using high-dose rate brachytherapy as ambulatory boost technique in conservative breast cancer treatment.

M. Espié, L. Quéro, S. Guillerm, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[Vitamin D and cancers].

M. Espié, F. Coussy, J. Wassermann, 2013, Presse medicale.

The evolving role of PET/CT in breast cancer

D. Groheux, M. Espié, E. Hindié, 2010, Nuclear medicine communications.

[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].

M. Espié, X. Pivot, J. Pierga, 2012, Bulletin du cancer.

Gemcitabine–Oxaliplatin Combination in Heavily Pretreated Metastatic Breast Cancer: A Pilot Study on 43 Patients

M. Espié, P. Cottu, J. Misset, 2007, The breast journal.

Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study)

M. Espié, D. Spaeth, F. Scotté, 2017, Supportive Care in Cancer.

Cancer Risk in Women Exposed to Diethylstilbestrol in Utero.

M. Espié, B. Asselain, P. Grosclaude, 2015, Therapie.

Impact of radical surgery on outcome in locally advanced breast cancer patients without metastasis at the time of diagnosis.

D. Groheux, M. Espié, S. Giacchetti, 2015, Anticancer research.

[Breast lobular carcinoma in situ: diagnosis and evolution].

M. Espié, A. de Roquancourt, S. Giacchetti, 2005, Gynecologie, obstetrique & fertilite.

Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer

M. Espié, M. Campone, J. Cortés, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

M. Espié, A. Awada, S. Delaloge, 2016, Clinical breast cancer.

Advances in vinca-alkaloids: Navelbine.

M. Espié, M. Marty, J. Extra, 1989, Nouvelle revue francaise d'hematologie.

Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.

M. Espié, M. Marty, J. Pierga, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does purified Swedish pollen extract, a nonhormonal treatment for vasomotor symptoms, inhibit the CYP2D6 enzyme system?

M. Espié, S. Goldstein, R. Druckmann, 2015, Menopause.

vasomotor symptoms , inhibit the CYP 2 D 6 enzyme system ? 1 2 3 Druckmann

M. Espié, S. Goldstein, R. Druckmann, 2015 .

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

M. Espié, Sung-Bae Kim, A. Schneeweiss, 2015, The Lancet. Oncology.

Incidence, risk factors, and outcomes of central venous catheter‐related thromboembolism in breast cancer patients: the CAVECCAS study

M. Espié, S. Chevret, D. Farge, 2017, Cancer medicine.

Treating Breast Cancer During Pregnancy

M. Espié, C. Cuvier, 1998, Drug safety.

[Diffusion-weighted MR imaging of the breast].

M. Espié, P. Bourrier, E. de Kerviler, 2010, Journal de radiologie.

Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas.

M. Espié, C. Gisselbrecht, P. Rousselot, 2003, The hematology journal : the official journal of the European Haematology Association.

Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

M. Espié, M. Edelman, F. Reyal, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concomitant chemoradiotherapy in locally advanced head and neck cancers: a prospective study of 68 patients

M. Espié, M. Marty, C. Hennequin, 1994 .

[Cancer of the breast: intensive treatment with bone marrow autografts].

M. Espié, C. Gisselbrecht, M. Marty, 1989, Bulletin du cancer.

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.

M. Espié, D. Amadori, R. Coombes, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[PET/CT in breast cancer: an update].

D. Groheux, M. Espié, E. Hindié, 2009, Bulletin du cancer.

Cowden disease and Lhermitte Duclos disease, markers of breast carcinoma: report of two patients.

M. Espié, M. Marty, A. de Rocquancourt, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer

Isabelle Thomassin, Marc Espié, Eric de Kerviler, 2013, European Radiology.

Vinorelbine in pregnancy.

M. Espié, M. Marty, C. Cuvier, 1997, European journal of cancer.

Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.

M. Espié, R. Porcher, S. Giacchetti, 2014, Reproductive biomedicine online.

Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies.

M. Espié, R. Porcher, S. Giacchetti, 2016, Reproductive biomedicine online.

Hereditary epidermolytic palmoplantar keratoderma associated with breast and ovarian cancer in a large kindred

M. Espié, P. Kerbrat, C. Blanchet‐Bardon, 1987, The British journal of dermatology.

Unusual presentations of thoracic tumors: Case 3. Parenchymal lipoma of the lung.

M. Espié, V. Meignin, A. Guermazi, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dysgerminoma in a pure 45,X Turner syndrome: report of a case and review of the literature.

M. Espié, M. Marty, J. Pierga, 1994, Gynecologic oncology.

p53 in breast cancer subtypes and new insights into response to chemotherapy.

Raphaël Porcher, Marc Espié, Philippe Bertheau, 2013, Breast.

Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?

M. Espié, A. Roquancourt, M. Marty, 2004, Breast Cancer Research and Treatment.

Molecular Profiling of Inflammatory Breast Cancer

Rosette Lidereau, M. Espié, I. Bièche, 2004, Clinical Cancer Research.

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

M. Espié, Sung-Bae Kim, J. Baselga, 2017, The Lancet. Oncology.

BMC Cancer BioMed Central Research article NF-kappa B genes have a major role in Inflammatory Breast Cancer

Rosette Lidereau, M. Espié, S. Vacher, 2008 .

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen

M. Espié, D. Rickman, A. de Roquancourt, 2007, PLoS medicine.

TP53 Status and Response to Chemotherapy in Breast Cancer

Jacqueline Lehmann, Marc Espié, Philippe Bertheau, 2008, Pathobiology.

A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases

M. Espié, M. Ziol, A. Janin, 2019, Clinical Cancer Research.

Estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative breast tumors

M. Hatt, D. Visvikis, D. Groheux, 2013, Cancer.

Estrogen receptor-positive / HER 2-negative breast tumors : Early prediction of chemosensitivity with 18 F-FDG PET / CT during neoadjuvant chemotherapy Running title : FDG-PET / CT for luminal breast cancer

M. Hatt, D. Visvikis, C. Rest, 2013 .

High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers: an innovative target

M. Espié, He Lu, A. Janin, 2019, Oncotarget.

Abstract P5-19-07: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3

M. Espié, Sung-Bae Kim, A. Schneeweiss, 2015 .

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15

Raphaël Porcher, Marc Espié, Philippe Bertheau, 2013, Breast Cancer Research.

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen

M. Espié, R. Porcher, A. de Roquancourt, 2014, British Journal of Cancer.

Long-term survival of advanced triple- negative breast cancers with a dose-intense cyclophosphamide/anthracycline

M. Espié, R. Porcher, M. Marty, 2014 .

Nonpalpable breast lesions: impact of a second-opinion review at a breast unit on BI-RADS classification

M. Espié, S. Giacchetti, C. Cuvier, 2021, European Radiology.

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy

D. Groheux, M. Espié, S. Chevret, 2022, Cancers.

Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer

D. Groheux, P. Merlet, M. Espié, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.

M. Hatt, D. Groheux, P. Merlet, 2014, European journal of cancer.

Triple-Negative Breast Cancer: Early Assessment with 18F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse

D. Groheux, M. Espié, E. Hindié, 2012, The Journal of Nuclear Medicine.

Changes in allelic imbalances in locally advanced breast cancers after chemotherapy

M. Espié, A. de Roquancourt, J. Misset, 2007, British Journal of Cancer.

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

M. Espié, X. Pivot, J. Pierga, 2011, British journal of clinical pharmacology.

TAMOXIFEN AND ARTERIAL THROMBOSIS

M. Espié, L. Mignot, D. Houlbert, 1985, The Lancet.

Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal–epithelial interactions

M. Espié, G. Millot, S. Chevret, 2001, The Journal of pathology.

Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer

M. Espié, A. de Roquancourt, S. Giacchetti, 2017, Oncotarget.

Two prognostic groups of inflammatory breast cancer have distinct genotypes.

M. Espié, I. Bièche, M. Marty, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evidence of chromosome regions and gene involvement in inflammatory breast cancer

M. Espié, I. Bièche, M. Marty, 2002, International journal of cancer.

Distinct tumor protein p53 mutants in breast cancer subgroups

M. Espié, C. Sotiriou, L. Pusztai, 2013, International journal of cancer.

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer

M. Espié, A. Roquancourt, I. Bièche, 2002, Oncogene.

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

M. Espié, M. Mathieu, M. Marty, 2010, Breast Cancer Research and Treatment.

18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials

D. Groheux, M. Espié, E. Hindié, 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[Dermatoses of the nipple and the areola].

M. Espié, M. Rybojad, F. Cordoliani, 1995, Archives d'anatomie et de cytologie pathologiques.

Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)

M. Espié, F. Reyal, B. Asselain, 2021, medRxiv.

High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients.

M. Espié, L. Zelek, M. Marty, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of gemcltabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containlng regimens

M. Espié, M. Namer, P. Fumoleau, 1997 .

High dose chemotherapy with stem-cell transplantation in a metastatic medulloblastoma in an adult: a case report and review of the literature

M. Espié, M. Marty, S. Giacchetti, 2005, Journal of Neuro-Oncology.

Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.

M. Espié, D. Spaeth, X. Pivot, 2017, European journal of cancer.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

M. Espié, D. Khayat, G. Romieu, 2013, The Lancet. Oncology.

Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial

M. Espié, F. Bidard, J. Pierga, 2019, General Session Abstracts.

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.

M. Espié, M. Desilvio, H. Burris, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim

Marc Espié, Domenico Rubello, D. Groheux, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Complete pathological response according to hormonal status, c-erbB2 and P53 in two neoadjuvant treatments in locally advanced breast cancers.

M. Espié, A. Roquancourt, M. Marty, 2009 .

Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer

D. Groheux, P. Merlet, M. Espié, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study

M. Espié, A. Roquancourt, A. de Roquancourt, 2001, British Journal of Cancer.

The Sentinel Node Procedure in Breast Cancer: Nuclear Medicine as the Starting Point

D. Groheux, M. Espié, E. Hindié, 2011, The Journal of Nuclear Medicine.

18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients

D. Groheux, P. Merlet, M. Espié, 2018, Oncotarget.

Breast cancer and HIV infection: two case reports.

M. Espié, M. Marty, C. Cuvier, 1997, European journal of cancer.

[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].

M. Espié, D. Cox, R. Rouzier, 2016, Bulletin du cancer.

Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.

M. Espié, D. Khayat, G. Romieu, 2015, European journal of cancer.

BI-RADS categorisation of 2708 consecutive nonpalpable breast lesions in patients referred to a dedicated breast care unit

C. de Bazelaire, M. Albiter, M. Espié, 2011, European Radiology.

Breast Intracystic Papillary Carcinoma: An Update

M. Espié, J. Calderaro, A. de Roquancourt, 2009, The breast journal.

Lymphoscintigraphy can select breast cancer patients for internal mammary chain radiotherapy.

D. Groheux, M. Espié, E. Hindié, 2012, International journal of radiation oncology, biology, physics.

Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors.

M. Espié, F. Reyal, B. Asselain, 2022, Reproductive Biomedicine Online.

Diagnostic strategy for the assessment of axillary lymph node status in breast cancer.

M. Espié, P. Bourrier, E. de Kerviler, 2015, Diagnostic and interventional imaging.

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.

M. Espié, A. Monnier, M. Marty, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose-rate brachytherapy for early breast cancer: an ambulatory technique.

M. Espié, M. Marty, M. Housset, 1999, International journal of radiation oncology, biology, physics.

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.

M. Espié, V. Ganju, P. Conte, 2013, Anticancer research.

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

M. Espié, G. Romieu, I. Pauporté, 2018, Breast.

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial

M. Espié, P. Conte, P. Conte, 2009, British Journal of Cancer.

2130 POSTER Updated analysis of an international phase II study evaluating an all-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer (MBC)

M. Espié, P. Conte, A. Chan, 2007 .

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.

M. Espié, M. Campone, T. Petit, 2006, Breast.

Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC

M. Espié, A. de Roquancourt, S. Giacchetti, 2020, Cancers.

The Chinese Monoid

Daniel Krob, Julien Cassaigne, Jean-Christophe Novelli, 2001, Int. J. Algebra Comput..

[Hormonal replacement therapy in menopause after breast cancer: first french study].

M. Espié, M. Marty, N. Bedairia, 1998, Contraception, fertilite, sexualite.

Performance of F dG Pet /Ct in the Clinical management of Breast Cancer 1

D. Groheux, M. Espié, S. Giacchetti, 2013 .

Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer

D. Groheux, P. Merlet, M. Espié, 2012, Journal of the National Cancer Institute.

Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.

M. Espié, R. Coombes, A. Tres, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contraception after breast cancer: a retrospective review of the practice among French gynecologists in the 2000's.

M. Espié, S. Giacchetti, A. Hamy, 2014, European Journal of Gynaecological Oncology.

Triple-negative breast cancer: Early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathological complete response

D. Groheux, M. Espié, E. Hindié, 2011 .

18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen

Matthieu Resche-Rigon, Marc Espié, Pascal Merlet, 2016, The Journal of Nuclear Medicine.

139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)

M. Espié, A. Tan, S. Im, 2020 .

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

D. Groheux, A. Martineau, P. Merlet, 2017, Breast Cancer Research.

Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.

M. Hatt, D. Visvikis, M. Majdoub, 2015, Radiology.

ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL

M. Espié, M. Dowsett, R. Gelber, 2012 .

Megestrol acetate in advanced breast carcinoma.

M. Espié, 1994, Oncology.

Treatment of breast cancer during pregnancy

M. Espié, C. Cuvier, 1996, Contraception, fertilite, sexualite.

Fluoxetin-induced pulmonary granulomatosis.

M. Espié, J. Trédaniel, G. Zalcman, 1996, The European respiratory journal.

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.

M. Espié, D. Khayat, G. Romieu, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

M. Espié, M. Bollet, F. Bidard, 2019, Breast Cancer Research.

Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.

D. Groheux, M. Espié, E. Hindié, 2008, International journal of radiation oncology, biology, physics.

Breast cancer incidence and hormone replacement therapy: Results from the MISSION study, prospective phase

M. Espié, J. Daurès, P. Marés, 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

High-dose adjuvant chemotherapy for breast cancer: state of the art.

M. Espié, P. Cottu, C. Cuvier, 2002, Forum.

Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.

M. Espié, M. Marty, C. Cuvier, 1998, In vivo.

Transcriptomic Profiles and Circulating Tumor Cell Detection in Primary Breast Cancer.

M. Espié, F. André, F. Reyal, 2009 .

BMC Cancer BioMed Central Research article NF-kappa B genes have a major role in Inflammatory Breast Cancer

M. Espié, S. Vacher, I. Bièche, 2008 .

Comparison of clinicopathological (CP) features and outcome of breast cancers (BC) in BRCA-mutation carriers patients, with a family history without BRCA-mutation and with sporadic disease.

M. Espié, S. Giacchetti, C. Cuvier, 2018 .

Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?

D. Groheux, M. Espié, E. Hindié, 2021, The Journal of the National Comprehensive Cancer Network.

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).

M. Espié, Sung-Bae Kim, J. Baselga, 2018 .

First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study.

M. Espié, N. Bogdanova, V. Semiglazov, 2012 .

[Exquisite sensitivity of TP53 mutant breast cancers to dose-dense chemotherapy].

M. Espié, J. Lehmann-Che, H. de Thé, 2007, Medecine sciences : M/S.

Metastatic Breast Cancer: Patient Journey, Patient Needs, and Expectations: Results of the RÉALITÉS National Survey

M. Espié, V. Diéras, N. Zernik, 2018, Oncologie.

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.

M. Espié, A. Monnier, M. Marty, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P4-06-06: Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation

M. Espié, F. Lévi, S. Giacchetti, 2017 .

Performance of FDG PET/CT in the clinical management of breast cancer.

D. Groheux, M. Espié, E. Hindié, 2013, Radiology.

Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions

M. Espié, S. Michiels, C. Coutant, 2020, Annals of Surgical Oncology.

Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.

M. Hatt, D. Groheux, P. Merlet, 2014, European journal of cancer.

Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

Breast cancer in postmenopausal women with and without hormone replacement therapy: Preliminary results of the MISSION study

M. Espié, J. Daurès, P. Marés, 2006, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

M. Hatt, F. Tixier, D. Visvikis, 2015, European Journal of Nuclear Medicine and Molecular Imaging.